OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time

Rhea-AI Summary

OpGen, Inc. (NASDAQ: OPGN) announced a business update alongside its fourth quarter and full year 2021 financial results to be reported after the U.S. markets close on March 29, 2022. A live conference call and audio webcast will take place at 4:30 PM ET to discuss financial outcomes and business updates. Following the call, a replay will be available until April 12, 2022. OpGen specializes in molecular diagnostics and bioinformatics to tackle infectious diseases, focusing on solutions for multidrug-resistant microorganisms.

Positive

• Scheduled financial results presentation could indicate transparency and active communication with stakeholders.
• Focus on precision medicine and infectious disease solutions addresses a critical healthcare need.

Negative

• No specific financial metrics or guidance disclosed in the PR, leaving uncertainty about the company's performance.

ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2021 financial results after the close of the U.S. financial markets on Tuesday, March 29^th, 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
U.S. Dial-in Number:	1-877-705-6003
International Dial-in Number:	1-201-493-6725
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1525984&tp_key=2d6460e1c0
Conference ID:	13726634
Replay Details
U.S. Dial-in Number:	1-844-512-2921
International Dial-in Number:	1-412-317-6671
Replay PIN:	13726634

Following the conclusion of the conference call, a replay will be available through April 12, 2022. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero^®, Acuitas^® AMR Gene Panel and the ARES Technology Platform including ARESdb^®, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com

FAQ

When will OpGen report its fourth quarter and full year 2021 financial results?

OpGen will report its financial results after the close of U.S. markets on March 29, 2022.

What time is OpGen's conference call regarding financial results?

The conference call is scheduled for 4:30 PM Eastern Time on March 29, 2022.

How can I access OpGen's conference call?

The conference call can be accessed via U.S. dial-in at 1-877-705-6003 or through the webcast at their website.

What is the focus of OpGen's business activities?

OpGen focuses on molecular diagnostics and bioinformatics to combat infectious diseases and multidrug-resistant organisms.